November 1, 2010

ACLASTA (zoledronic acid 5mg/100mL) solution for intravenous infusion – Association with renal dysfunction

Novartis in collaboration with Health Canada, is notifying healthcare professionals and the public of reports of renal impairment and renal failure requiring dialysis or with fatal outcome that occurred in patients with history of renal impairment or other risk factors receiving ACLASTA (zoledronic acid).

Related Articles:

Acute Kidney Injury

Comments are closed.